LBS 007

Drug Profile

LBS 007

Alternative Names: LBS-007

Latest Information Update: 30 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Columbia University Medical Center; Memorial Sloan-Kettering Cancer Center
  • Developer Columbia University Medical Center; Lin Bioscience; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics
  • Mechanism of Action CDC7 protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 24 Apr 2018 LBS 007 receives Orphan Drug status for Precursor cell lymphoblastic leukaemia-lymphoma in USA
  • 24 Apr 2018 Lin BioScience plans a phase I trial for Haematological malignancies in the fourth quarter of 2018
  • 03 Mar 2017 LBS 007 licensed to Lin Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top